Seven Hound Ventures

Seven Hound Ventures is an early-stage venture capital firm that partners with founders building transformative companies across high-growth technology sectors. Operating under the domain 7hventures.co, the firm focuses on conviction-first investing, identifying exceptional entrepreneurs tackling large, meaningful problems and backing them with capital and strategic support from the earliest stages of company formation.

The firm's investment thesis spans several frontier sectors including artificial intelligence, biotechnology, longevity and healthspan, fintech, and frontier technology. Seven Hound Ventures has established a notable track record with over 40 investments, three NASDAQ IPOs, and four acquisitions generating more than $2.4 billion in combined acquisition value.

Among its most prominent portfolio outcomes, the firm backed Tilray, which became the first cannabis company to complete an IPO on NASDAQ in 2018. In the psychedelic medicine space, Seven Hound Ventures supported both MindMed and ATAI Life Sciences, both of which achieved NASDAQ listings in 2020 and 2021 respectively. Additional portfolio exits include Beckley Psytech, acquired by ATAI Life Sciences in 2025; Gilgamesh, acquired by AbbVie for approximately $1.2 billion in 2025; Transcend, acquired by Otsuka for approximately $1.225 billion in 2026; and The Block, the crypto media outlet acquired by Foresight Ventures in 2023.

The firm's approach centers on early identification of category-defining founders and long-term partnership rather than opportunistic deal flow. While not a CPG or consumer packaged goods supplier, Seven Hound Ventures operates at the intersection of deep technology and life sciences venture investing, with particular strength in biotech and frontier health innovation.